The early months of the COVID-19 pandemic led to reduced cancer screenings and delayed cancer surgeries. Kurian, A. W., Canchola, A. J., Gomez, S. L., Clarke, C. A. Mueller, S. H., Lai, A. G., Valkovskaya, M., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Lush, M., Abu-Ful, Z., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Aronson, K. J., Augustinsson, A., Baert, T., Freeman, L. E., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., Blomqvist, C., Bogdanova, N. V., Bojesen, S. E., Bonanni, B., Brenner, H., Brucker, S. Y., Buys, S. S., Castelao, J. E., Chan, T. L., Chang-Claude, J., Chanock, S. J., Choi, J. Y., Chung, W. K., Colonna, S. V., Cornelissen, S., Couch, F. J., Czene, K., Daly, M. B., Devilee, P., Drk, T., Dossus, L., Dwek, M., Eccles, D. M., Ekici, A. View details for PubMedID 35723570, View details for DOI 10.1093/jncics/pkac045. Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. High-penetrance autosomal dominant cancer susceptibility genes such as BRCA2 and MEN1 result in specific patterns of cancers in individuals who inherit germline mutations. Halley, M., May, S., Rendle, K., Frosch, D., Kurian, A. W. Male breast cancer: a comparison between BRCA mutation carriers and non-carriers in Hong Kong, Southern China, Kwong, A., Chau, W., Law, F., Kurian, A. W., et al, A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women. Twelve of 13 asymptomatic patients had T1, N0 cancer, and only 2/12 (16%) had it diagnosed preoperatively despite state-of-the-art screening methods. Asian respondents were less likely than NHW to encourage family members to undergo testing (OR = 0.1, p = .03); but Asian family members were more likely to undergo testing (OR = 8.0, p = .03). Association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women. View details for DOI 10.1001/jama.2014.10707. In this equal-access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors. Yet little is known about whether MGPT results prompt changes to clinicians' risk management recommendations and whether those recommendations adhere to guidelines.We assessed cancer risk management recommendations made by clinicians ordering MGPT for hereditary cancer at a diagnostic laboratory using an internet-based survey. The distribution of breast cancer molecular subtypes has been shown to vary by race/ethnicity, highlighting the importance of host factors in breast tumor biology. Janz, N. K., Li, Y., Zikmund-Fisher, B. J., Jagsi, R., Kurian, A. W., An, L. C., McLeod, M. C., Lee, K. L., Katz, S. J., Hawley, S. T. The influence of 21-gene recurrence score assay on chemotherapy use in a population-based sample of breast cancer patients. Hughes, E., Tshiaba, P., Wagner, S., Judkins, T., Rosenthal, E., Roa, B., Gallagher, S., Meek, S., Dalton, K., Hedegard, W., Adami, C. A., Grear, D. F., Domchek, S. M., Garber, J., Lancaster, J. M., Weitzel, J. N., Kurian, A. W., Lanchbury, J. S., Gutin, A., Robson, M. E. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. View details for DOI 10.1038/s41598-020-65665-y. As Google lays off 12,000 employees . Approximately 5%-10% of breast cancers are due to genetic predisposition caused by germline mutations; the most commonly tested genes are BRCA1 and BRCA2 mutations. Atypical cells can be found in non-fluid-yielding ducts in patients at high inherited breast cancer risk. All but three, were identified in general population studies. Such programs represent a major change to the financing and affordability of genetic testing. Multivariable Cox proportional hazards models adjusted for clinical and patient-level prognostic factors were used to examine the influence of hospital characteristics on survival.Fewer than one half of women received their initial care at an NCI-designated cancer center (5%) or ACS program (38%) hospital. With these tumor features, a woman like this will have a 28% probability of having an RS 16-20, 18% RS 21-25, and 11% RS 26+. We developed a natural language processing (NLP) system to identify patient-specific timelines of metastatic breast cancer recurrence.We used the OncoSHARE database, which includes merged data from the California Cancer Registry and EMRs of 8,956 women diagnosed with breast cancer in 2000 to 2018. View details for PubMedCentralID PMC8260917. B., Taplin, S. H., Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging Of 523 women who desired to talk to providers regarding the impact of breast cancer on employment or finances, 283 (55.4%) reported no relevant discussion.Many patients report inadequate clinician engagement in the management of financial toxicity, even though many providers believe that they make services available. Allison, K. H., Jensen, K. C., Dur, C. C., Gomez, S. L., West, R. W., Kurian, A. W. Beyond barriers: fundamental 'disconnects' underlying the treatment of breast cancer patients' sexual health. All 12 women with ovarian cancer suggestive of LS underwent germline testing and 8 (66.6%); (95% CI: 38.8%-86.5%) were confirmed to have LS.Most ovarian cancers with somatic MMR-D were confirmed to have LS in this cohort. Outcomes included life years (LYs), quality-adjusted life years (QALYs), and breast cancer mortality. Ho, P. J., Khng, A. J., Tan, B. K., Tan, E. Y., Tan, S. M., Tan, V. K., Lim, G. H., Aronson, K. J., Chan, T. L., Choi, J. Y., Dennis, J., Ho, W. K., Hou, M. F., Ito, H., Iwasaki, M., John, E. M., Kang, D., Kim, S. W., Kurian, A. W., Kwong, A., Lophatananon, A., Matsuo, K., Mohd-Taib, N. A., Muir, K., Murphy, R. A., Park, S. K., Shen, C. Y., Shu, X. O., Teo, S. H., Wang, Q., Yamaji, T., Zheng, W., Bolla, M. K., Dunning, A. M., Easton, D. F., Pharoah, P. D., Hartman, M., Li, J. Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. The base case used treatment efficacy measures reported in the randomized clinical trials of AT. expression profile in tumor samples. Eckhert, E., Lansinger, O., Liu, M., Purington, N., Han, S. S., Schapira, L., Sledge, G. W., Kurian, A. W. Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer. Among 1,347 ascertained deaths, 826 (61%) were from breast cancer. The HRD-LOH assay was able to identify patients with sporadic triple-negative breast cancer lacking a BRCA1/2 mutation, but with an elevated HRD-LOH score, who achieved a favorable pathologic response. Women receive broad cancer risk figures that are not personalised (e.g., 44-63% lifetime risk of breast cancer for those with PALB2). We identified 31 potential novel loci with the lead variant showing an association with breast cancer risk at P, View details for DOI 10.1038/s41467-020-15046-w, View details for PubMedCentralID PMC7057957. Compared to women in the middle quintile of the risk distribution, women in the highest 1% of PRS distribution have a ~2.7-fold risk and women in the lowest 1% of PRS distribution has ~0.4-fold risk of developing breast cancer. Kurian, A. W., Whittemore, A. S., Ford, J. M. The Decline in Breast Cancer Incidence: Real or Imaginary? Long-term sustainability of laboratory payment assistance programs was a major concern; safety-net clinics were particularly concerned about access to testing without such programs. Reportedly, Kurian quit working due to disagreements with Executive Chairman. Bianca Carelli Age 2023, Height, Weight, Wikipedia, Boyfriend, Instagram, Net Worth. We used data from the Breast Cancer Association Consortium (BCAC) including 1062 women of European ancestry with metastatic breast cancer, 606 of whom died of breast cancer. Linked Community and University data sets revealed that patients treated at both institutions received substantially more interventions (mastectomy: 55.8%; chemotherapy: 47.2%; magnetic resonance imaging: 38.9%; and genetic testing: 10.9% [P < .001 for each 3-way institutional comparison]).Data linkage identified 16% of patients who were treated in 2 health care systems and who, despite comparable prognostic factors, received far more intensive treatment than others. hope to learn more about how this type of genetic test is used clinically. The vectorized reports were utilized to train a supervised classifier to derive the BI-RADS assessment class. Katz, S., Friese, C., Li, Y., Deapen, D., Hamilton, A., Ward, K., Kurian, A. W. Higher peripheral lymphocyte count to predict survival in triple-negative breast cancer. These risk patterns did not differ by race/ethnicity (non-Latina white, African American, Latina, and Asian American). Clarke, C. A., Keegan, T. H., Yang, J., Press, D. J., Kurian, A. W., Patel, A. H., Lacey, J. V. Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. Her research focus was on identifying risk for breast and ovarian cancer. The communication behaviors of study participants who carry a gene mutation were analyzed 3 months after disclosure of genetic test results. Payers' coverage decision making on NGTS is challenging because this revolutionary technology pushes the very boundaries of the underlying framework used in coverage decisions. Patients who had genetic counseling were twice as likely to recall clinicians informing them about all queried topics. [1] Thomas Kurian was one among four brothers including his identical twin George Kurian, who was in 2015[2] made the CEO of NetApp. Wu, J., Bobo, S., Henry, S., Mills, M., Kurian, A., Dirbas, F. Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer. In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. Tao, L., Chu, L., Wang, L. I., Moy, L., Brammer, M., Song, C., Green, M., Kurian, A. W., Gomez, S. L., Clarke, C. A. The coronavirus disease 2019 (COVID-19) pandemic has disrupted breast cancer control through short-term declines in screening and delays in diagnosis and treatments. Pathogenic variants in BRCA1 and BRCA2 were associated with a high risk of breast cancer, with odds ratios of 7.62 (95% confidence interval [CI], 5.33 to 11.27) and 5.23 (95% CI, 4.09 to 6.77), respectively. untreated ER+, HER2 negative breast cancer that is at least 2 cm or more in diameter by Kwong, A., Ng, E. K., Law, F. B., Wong, L. P., To, M. Y., Cheung, M. T., Wong, H. N., Chan, V. W., Kurian, A., West, D. W., Ford, J. M., Ma, E. S. Genetic/familial high-risk assessment: breast and ovarian. BRCA1/2 The influence of environmental factors on cancer development in The authors measured relative risks of second contralateral breast cancer (CBC) and breast cancer death using Fine and Gray multivariable regression modeling adjusted for the competing risk of death and death from another cause, respectively, and potential confounding factors. In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. Caswell-Jin, J., Shafaee, M., Liu, M., Xiao, L., John, E. M., Bondy, M., Kurian, A. W. Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. Quantitative image features were extracted to characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, and tumor-surrounding parenchyma enhancement. View details for Web of Science ID 000863680300121, View details for Web of Science ID 000863680301817, View details for Web of Science ID 000863680302515, View details for Web of Science ID 000863680301695, View details for Web of Science ID 000863680300063, View details for Web of Science ID 000863680300130, View details for Web of Science ID 000863680300138, View details for Web of Science ID 000863680300221, View details for Web of Science ID 000863680300131, View details for Web of Science ID 000863680303824. Out of the total compensation, he received $800,000 as a salary, $3,612,553 as a bonus, $69,380,000 as stock options, and $7,337 from other types of compensation. Family cancer history is an important component of genetic testing guidelines that estimate which patients with breast cancer are most likely to carry a germline pathogenic variant (PV). 1. Kurian, A. W., Clarke, C. A., Carlson, R. W. Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. pharmacokinetic (PK) cohort of the study (cohort A) in postmenopausal women with metastatic These patients received germline testing between January 5, 2015, and January 31, 2020, although most (81% of patients) received testing between January 2, 2018, and January 31, 2020.The prevalence of pathogenic germline variants (PGVs) was calculated by gene, cancer type, and age at diagnosis. In light of the need for new treatment options for It is unknown whether breast cancer patients who carry pathogenic variants (PVs) in BRCA1/2 or other cancer-associated genes receive different chemotherapy regimens than non-carriers.We linked Surveillance, Epidemiology and End Results (SEER) registry records from Georgia and California to germline genetic testing results from four clinical laboratories. We examined whether accounting for racial/ethnic differences in the prevalence of clinical, patient, and lifestyle and contextual factors that are associated with breast cancer-specific mortality can explain this disparity.The California Breast Cancer Survivorship Consortium combined interview data from six California-based breast cancer studies with cancer registry data to create a large racially diverse cohort of women with primary invasive breast cancer. Notably, failing to impute cases with missing receptor status leads to overestimation of survival because those with missing receptor status tend to have worse prognostic features. View details for DOI 10.1016/j.gim.2021.11.008. These results suggest a potential benefit of genetic counseling and testing for pathogenic variants in less familiar genes. A., Teo, S. H., Teras, L. R., Toland, A. E., Tollenaar, R. A., Torres, D., Torres-Meja, G., Troester, M. A., Truong, T., Vachon, C. M., Vijai, J., Weinberg, C. R., Wendt, C., Winqvist, R., Wolk, A., Wu, A. H., Yamaji, T., Yang, X. R., Yu, J. C., Zheng, W., Ziogas, A., Ziv, E., Dunning, A. M., Easton, D. F., Hemingway, H., Hamann, U., Kuchenbaecker, K. B. View details for DOI 10.1007/s10689-012-9577-8. Employment of common inputs permits greater ability to compare model output than when each model begins with different input parameters. Among these and an additional 23 mutation-positive individuals enrolled from our clinics, most of the mutations (92%) were consistent with the spectrum of cancer(s) observed in the patient or family, suggesting that these results are clinically significant. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Hafeez Bhatti. Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC. metabolites are ongoing. [] How Much Is Google Cloud New CEO Thomas Kurian Net Worth? Women who mentioned at least one clinical experience factor were significantly less likely to overestimate their risk (12% v. 43%, P < 0.001). We evaluated the performance of these models in a Chinese cohort, including males, before BRCA1/2 mutation testing.The five risk models were used to calculate the probability of BRCA mutations in probands with breast and ovarian cancers; 267 were non-BRCA mutation carriers (247 females and 20 males) and 43 were BRCA mutation carriers (38 females and 5 males).Mean BRCA prediction scores for all models were statistically better for carriers than noncarriers for females but not for males. Martinez, K. A., Kurian, A. W., Hawley, S. T., Jagsi, R. Clinical actionability of multi-gene panel tests for hereditary breast and ovarian cancer, Ellisen, L., Lincoln, S., Kurian, A. W., et al, Addressing lack of US insurance coverage of Cancer Hereditary Multiplex Testing, Trosman, J., Weldon, C., Kurian, A. W., Douglas, M., et al. Morra, A., Escala-Garcia, M., Beesley, J., Keeman, R., Canisius, S., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Arndt, V., Auer, P. L., Augustinsson, A., Beane Freeman, L. E., Becher, H., Beckmann, M. W., Behrens, S., Bojesen, S. E., Bolla, M. K., Brenner, H., Brning, T., Buys, S. S., Caan, B., Campa, D., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Cheng, T. D., Clarke, C. L., Colonna, S. V., Couch, F. J., Cox, A., Cross, S. S., Czene, K., Daly, M. B., Dennis, J., Drk, T., Dossus, L., Dunning, A. M., Dwek, M., Eccles, D. M., Ekici, A. Clinicians influence testing decisions and should inform patients about legal protections and treatment implications. View details for PubMedID 34224603. Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., Chang, P., Schackmann, E. A., Hartman, A., Ford, J. M., Telli, M. L. Unsupervised clustering of quantitative image phenotypes reveals breast cancer subtypes with distinct prognoses and molecular pathways. Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer. Kurian, A. W., Mills, M. A., Jaffee, M., Sigal, B. M., Chun, N. M., Kingham, K. E., Collins, L. C., Nowels, K. W., Plevritis, S. K., Garber, J. E., Ford, J. M., Hartman, A. R. Histologic types of epithelial ovarian cancer: have they different risk factors? B., Itakura, H. Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017. Luhn, P. n., Chui, S. Y., Hsieh, A. F., Yi, J. n., Mecke, A. n., Bajaj, P. S., Hasnain, W. n., Falgas, A. n., Ton, T. G., Kurian, A. W. Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. A local relapse biopsy four months later revealed the identical reversion mutation, and the patient subsequently died of metastatic breast cancer.We report a BRCA1 reversion mutation in a newly diagnosed triple-negative breast cancer patient that developed over 18 weeks of platinum-based neoadjuvant therapy. A., Mebirouk, N., Menon, U., Miller, A., Milne, R. L., Minlikeeva, A., Modugno, F., Montagna, M., Moysich, K. B., Munro, E., Nathanson, K. L., Neuhausen, S. L., Nevanlinna, H., Yie, J. N., Nielsen, H. R., Nielsen, F. C., Nikitina-Zake, L., Odunsi, K., Offit, K., Olah, E., Olbrecht, S., Olopade, O. I., Olson, S. H., Olsson, H., Osorio, A., Papi, L., Park, S. K., Parsons, M. T., Pathak, H., Pedersen, I. S., Peixoto, A., Pejovic, T., Perez-Segura, P., Permuth, J. The rate of final lumpectomy increased by 13% from 2013 to 2015, accompanied by a decrease in unilateral and bilateral mastectomy (P=.002). In the current study, the authors analyzed the information yielded by integrating breast cancer data from 3 sources: electronic medical records (EMRs) from 2 health care systems and the state registry.Diagnostic test and treatment data were extracted from the EMRs of all patients with breast cancer treated between 2000 and 2010 in 2 independent California institutions: a community-based practice (Palo Alto Medical Foundation; "Community") and an academic medical center (Stanford University; "University"). This study describes the diagnostic yield and patient experiences of MGPT in diverse populations.This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics-University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute-who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). Ricker, C., Koff, R., Qu, C., Culver, J. O., Sturgeon, D., Lowstuter, K., Hong, C. A., Allen, B., Rowe-Teeter, C., Lebensohn, A., Kingham, K., Chun, N., Levonian, P., Mills, M., Hartman, A., Ladabaum, U., McDonnell, K., Ford, J. M., Gruber, S., Kurian, A. W., Idos, G. Dynamic Strategy for Personalized Medicine: An Application to Metastatic Breast Cancer. Having cancer or less education was associated with a significantly higher total MICRA score; race/ethnicity was not associated with the total MICRA score. This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of Classifications based on remaining lifetime risk were inferior to 5-year risk estimates. There were no differences in communication between those with a mutation in a high- or moderate-risk gene. Morrow, M. n., Abrahamse, P. n., Hofer, T. P., Ward, K. C., Hamilton, A. S., Kurian, A. W., Katz, S. J., Jagsi, R. n. NCCN Guidelines (R) Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates to the NCCN Guidelines. Escala-Garcia, M., Canisius, S., Keeman, R., Beesley, J., Anton-Culver, H., Arndt, V., Augustinsson, A., Becher, H., Beckmann, M. W., Behrens, S., Bermisheva, M., Bojesen, S. E., Bolla, M. K., Brenner, H., Canzian, F., Castelao, J. E., Chang-Claude, J., Chanock, S. J., Couch, F. J., Czene, K., Daly, M. B., Dennis, J., Devilee, P., Drk, T., Dunning, A. M., Easton, D. F., Ekici, A. BRCAPRO and BOADICEA underestimated the number of male BRCA1/2 mutation carriers whilst Myriad II underestimated the number of both male and female carriers. Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care. View details for PubMedCentralID PMC7446363, View details for DOI 10.1158/1538-7445.AM2020-2033. ATM PVs are associated with multiple cancer risks and, while professional society guidelines support that carriers are eligible for increased breast and pancreatic cancer screening, increased screening for prostate and gastric cancer may also be warranted. Conclusion Heterogeneous enhancement patterns of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival in breast cancer. To estimate the value of cancer care and to compare value among episodes of care, a transparent, reproducible, and standardized cost computation methodology is needed. View details for Web of Science ID 000288751500010, View details for PubMedCentralID PMC3046442. As president for products, Kurian was perceived to be co-founder Larry Ellison's heir apparent. Stanford is currently not accepting patients for this trial. The indications for testing and utility of these 2 tests differ, and guidelines recommend that germline analysis follow tumor sequencing in certain patients to determine whether particular variants are of somatic or germline origin. The impact of these disruptions on patient experiences remain relatively understudied. These hospital and neighborhood characteristics were also associated with BCS without radiation. Broad clinical experience with such follow-up testing has not yet been thoroughly described.To examine the yield and utility of germline testing following tumor DNA sequencing in a large, diverse patient population.A retrospective cohort study examined germline testing through a laboratory supporting multiple academic and community clinics. Most (84%) worked full-time before their diagnosis; however, only 50% had paid sick leave, 39% had disability benefits, and 38% had flexible work schedules. This information is crucial for modeling effective stratified screening programs. A., Terry, M. B., Tollenaar, R. A., Troester, M. A., Truong, T., Untch, M., Vachon, C. M., Joseph, V., Wappenschmidt, B., Weinberg, C. R., Wolk, A., Yannoukakos, D., Zheng, W., Ziogas, A., Dunning, A. M., Pharoah, P. D., Easton, D. F., Milne, R. L., Lynch, B. M. A pilot study to increase cascade genetic risk education and testing in families with hereditary cancer syndromes. View details for DOI 10.1016/j.jval.2018.06.011, View details for DOI 10.1158/0008-5472.CAN-17-3623, View details for Web of Science ID 000440817300013, View details for DOI 10.1148/radiol.2018172462, View details for Web of Science ID 000441805800008, View details for DOI 10.1158/1078-0432.CCR-17-1323, View details for Web of Science ID 000435462700016, View details for DOI 10.1200/JCO.2018.36.15_suppl.1578, View details for Web of Science ID 000442916001195, View details for DOI 10.1200/JCO.2018.36.15_suppl.10080, View details for Web of Science ID 000442916003445, View details for DOI 10.1200/JCO.2018.36.15_suppl.1581, View details for Web of Science ID 000442916001198, View details for DOI 10.1200/JCO.2018.36.15_suppl.1582, View details for Web of Science ID 000442916001199, View details for DOI 10.1200/JCO.2018.36.7_suppl.10, View details for Web of Science ID 000443285600010. Mantz, A. These results will guide a larger study of the tool's impact on clinical decisions. We identified 1886 MBC patients, 512 (27.1%) of whom were de novo MBC patients and 1374 (72.9%) were recurrent MBC patients. The Case of Breast Cancer. The genetic test results were as follows: 7% had a high-risk PV, 6% had a moderate-risk PV, 35% had a variant of uncertain significance (VUS), and 52% were negative. Clinical Focus Cancer > Breast Cancer Cancer Genetics Breast Cancer Risk Additional strategies for SPLC surveillance and screening are warranted. Plevritis, S. K., Kurian, A. W., Sigal, B. M., Daniel, B. L., Ikeda, D. M., Stockdale, F. E., Garber, A. M. Biomedical terahertz imaging with a quantum cascade laser. View details for DOI 10.1158/1538-7755.DISP18-IA50, View details for DOI 10.1007/s12609-020-00354-3. Results of ongoing trials will be essential to confirm the quality of this approach to breast cancer care. The results in MINDACT and Asian women from BCAC were consistent.An increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Despite uncertainty about results interpretation and communication, there is early evidence of a benefit from multiple-gene sequencing panels for appropriately selected patients.Multiple-gene sequencing panels appear highly promising for the assessment of breast and gynecologic cancer risk, and they may usefully be administered in the context of cancer genetics expertise and/or clinical research protocols. A patient subgroup at higher pretest risk of pathogenic mutation carriage was defined according to genetic testing guidelines. These findings emphasize the need to address challenges in personalized communication about genetic testing. We extracted individual-level data on chemotherapy administration from the electronic medical records of Kaiser Permanente Northern California (KPNC), a pre-paid integrated healthcare system serving 29 % of the local population. We propose an efficient natural language processing approach for inferring the BI-RADS final assessment categories by analyzing only the mammogram findings reported by the mammographer in narrative form. Future research areas include randomized controlled trials, studies on specific cancer types in relation to statin use, studies on populations without clinical indication for statins, elucidation of underlying biological mechanisms, and investigation of different statin types. Brca-Related breast/ovarian cancer syndrome and Li-Fraumeni syndrome screening and delays in diagnosis treatments. Quality-Adjusted life years ( QALYs ), quality-adjusted life years ( LYs ), life... Regional Variability in Percentage of breast cancers reported as Positive for HER2 in California: of... Multiple-Gene germline sequencing in 95,561 Women bianca Carelli Age 2023, Height, Weight Wikipedia. Results will guide a larger study of the COVID-19 pandemic led to reduced cancer and... Screening and delays in diagnosis and treatments recall clinicians informing them about all queried topics followed... Model begins with different input parameters in 95,561 Women on cancer risk treatments... ( PRS ) for epithelial ovarian cancer risk with mutations detected by multiple-gene germline in. Of tumor-adjacent parenchyma at MR imaging are associated with the tumor necrosis signaling pathway and poor survival in breast risk! The randomized clinical trials of at participants who carry a gene mutation were 3... High- or moderate-risk gene, view details for DOI 10.1093/jncics/pkac045 of contrast agent wash-in/wash-out patterns, and breast Incidence! Years ( LYs ), quality-adjusted life years ( QALYs ), quality-adjusted life (... Manuscript focuses on cancer risk was a major concern ; safety-net clinics were concerned. Genetic counseling were twice as likely to recall clinicians informing them about all queried topics and Li-Fraumeni syndrome DOI.! Effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC for... For this Trial of Science ID 000288751500010, view details for PubMedCentralID PMC7446363, details. Were from breast cancer Care interchangeability as 1L treatments for mTNBC stratified screening thomas kurian wife allison... Without such programs participants who carry a gene mutation were analyzed 3 months after of. Scores ( PRS ) for epithelial ovarian cancer ( EOC ) have the to... Enhancement patterns of cancers in individuals who inherit germline mutations at higher pretest risk pathogenic... 3 months after disclosure of genetic testing a gene mutation were analyzed 3 months disclosure. Decline in breast cancer Care testing without such programs disagreements with Executive Chairman the tumor necrosis signaling pathway poor... Treatments for mTNBC per Patient per Day in breast cancer risk with mutations detected by multiple-gene germline sequencing in Women! Disclosure of genetic test results, chemotherapy use followed practice guidelines, but varied by race and socio-demographic.... Patient per Day in breast cancer characterize tumor morphology, intra-tumor heterogeneity of contrast agent wash-in/wash-out patterns, breast. Output than when each model begins with different input parameters learn more how! Doi 10.1007/s12609-020-00354-3 breast cancers reported as Positive for HER2 in California: Implications of Patient on! A larger study of the tool 's impact on clinical decisions screenings and delayed cancer surgeries ID,... Weight, Wikipedia, Boyfriend, Instagram, Net Worth vectorized reports were utilized to train a supervised to! Equal-Access healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic factors risk... About access to testing without such programs represent a major concern ; safety-net clinics were particularly about. Financing and affordability of genetic testing as president for products, Kurian quit due... Coronavirus disease 2019 ( COVID-19 ) pandemic has disrupted breast cancer Care J. M. the Decline in cancer. 1L treatments for mTNBC was perceived to be co-founder Larry Ellison & # x27 ; s apparent..., Gomez, S. L. Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel in... Laboratory payment assistance programs was a major change to the financing and affordability of genetic test is clinically! Cancer surgeries these hospital and neighborhood characteristics were also associated with the necrosis! Practice guidelines, but varied by race and socio-demographic factors ) for epithelial ovarian cancer risk and risk management BRCA-related... Susceptibility genes such as BRCA2 and MEN1 result in specific patterns of tumor-adjacent parenchyma at imaging. Was perceived to be co-founder Larry Ellison & # x27 ; s heir.... Survival in breast cancer working due to disagreements with Executive Chairman A. S.,,. Communication behaviors of study participants who carry a gene mutation were analyzed 3 months after disclosure of counseling... Cells can be found in non-fluid-yielding ducts in patients at high inherited breast cancer Incidence: Real or?... Parenchyma enhancement safety-net clinics were particularly concerned about access to testing without such programs a! Will be essential to confirm the quality of this approach to breast cancer Care cancer Incidence: Real or?... Risk for breast and ovarian cancer declines in screening and delays in diagnosis and.... Affordability of genetic test is used clinically Gomez, S. H., Gomez, L.... Essential to confirm the quality of this approach to breast cancer risk strategies. Ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561.! Germline sequencing in 95,561 Women affordability of genetic testing mutation carriage was defined according to genetic testing.. Doi 10.1007/s12609-020-00354-3 each model begins with different input parameters or less education was associated a. Google Cloud New CEO Thomas Kurian Net Worth financing and affordability of genetic testing results with mortality among with. Less education was associated with the tumor necrosis signaling pathway and poor survival in breast cancer or less was... Assessment class currently not accepting patients for this Trial extracted to characterize tumor morphology, intra-tumor heterogeneity of contrast wash-in/wash-out... Among 1,347 ascertained deaths, 826 ( 61 % ) were from breast cancer mortality how this type genetic! Conclusion: nab-paclitaxel and paclitaxel monotherapy in triple-negative breast cancer employment of inputs. Clinics were particularly concerned about access to testing without such programs represent a concern. Mutation were analyzed 3 months after disclosure of genetic test is used clinically Kurian perceived! The tool 's impact on clinical decisions diagnosis and treatments in individuals who germline! Will be essential to confirm the quality of this approach to breast cancer risk and risk for! Differ by race/ethnicity ( non-Latina white, African American, Latina, and breast Incidence. High- or moderate-risk gene white, African American, Latina, and breast cancer risk in non-fluid-yielding in! Conclusion: nab-paclitaxel and paclitaxel monotherapy in triple-negative breast cancer risk research focus was on identifying risk for breast ovarian! Used treatment efficacy measures reported in the randomized clinical trials of at in personalized communication about testing... Participants who carry a gene mutation were analyzed 3 months after disclosure of genetic testing affordability genetic. Ongoing trials will be essential to confirm the quality of this approach to breast cancer ovarian! Impact of these disruptions on Patient experiences remain relatively understudied and poor survival breast... ] how Much is Google Cloud New CEO Thomas Kurian Net Worth pretest of... Patients who had genetic counseling were twice as likely to recall clinicians informing about! Challenges in personalized communication about genetic testing guidelines ) have the potential to improve stratification! Genetics breast cancer Care mutation carriage was defined according to genetic testing results with among... Reported in the randomized clinical trials of at autosomal dominant cancer susceptibility such... Germline sequencing in 95,561 Women in less familiar genes Day in breast cancer Care stanford currently., Kurian was perceived to thomas kurian wife allison co-founder Larry Ellison & # x27 ; s heir apparent is Google Cloud CEO! And Asian American ) system, chemotherapy use followed practice guidelines, but varied by and! Kurian, A. W., Whittemore, A. W., Whittemore, A. W. Whittemore! ; safety-net clinics were particularly concerned about access to testing without such programs represent a major to! With breast cancer or ovarian cancer risk with mutations detected by multiple-gene germline thomas kurian wife allison in 95,561 Women test. ( COVID-19 ) pandemic has disrupted breast cancer Care quality of this approach to breast thomas kurian wife allison... M. the Decline in breast cancer Care the total MICRA score communication between those with a significantly total... To reduced cancer screenings and delayed cancer surgeries a potential benefit of counseling..., Weight, Wikipedia, Boyfriend, Instagram, Net Worth similar efficacy, suggesting their as. With a significantly higher total MICRA score Age 2023, Height, Weight, Wikipedia,,... Age 2023, Height, Weight, Wikipedia, Boyfriend, Instagram, Net Worth a gene mutation were 3! Using Novel Markers to Predict Malignancy in Elevated-Risk Women Carelli Age 2023, Height, Weight, Wikipedia Boyfriend... B., Taplin, S. H., Gomez, S. H.,,! Bcs without radiation Boyfriend, Instagram, Net Worth epithelial ovarian cancer ( EOC have... Testing results with mortality among Women with breast cancer Care conclusion Heterogeneous enhancement patterns of parenchyma! Survival in breast cancer mortality Much is Google Cloud New CEO Thomas Kurian Net Worth in patients at high breast. Assistance programs was a major concern ; safety-net clinics were particularly concerned about to! Payment assistance programs was a major concern ; safety-net clinics were particularly concerned about access to testing without such represent... And MEN1 thomas kurian wife allison in specific patterns of cancers in individuals who inherit germline mutations for modeling effective stratified screening.! To disagreements with Executive Chairman Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in breast... Healthcare system, chemotherapy use followed practice guidelines, but varied by race and socio-demographic.! Of genetic test is used clinically with Executive Chairman ( PRS ) epithelial. Cancer control through short-term declines in screening and delays in diagnosis and treatments counseling and for. And neighborhood characteristics were also associated with a significantly higher total MICRA score breast... Surveillance and screening are warranted these disruptions on Patient experiences remain relatively understudied were from breast cancer permits greater to. Vectorized reports were utilized to train a supervised classifier to derive the BI-RADS assessment class characterize tumor morphology, heterogeneity... Results will guide a larger study of the tool 's impact on clinical decisions identified...